Impact of disease severity on gastric residual volume in critical patients

Table 1 Demographic data of the 61 study subjects (mean ± SE) n (%)

Average age (yr)	67.9 ± 2.0
Gender (male)	43/61 (70.1)
Body mass index (kg/m2)	23.1 ± 0.5
Diabetic patients	22/61 (36.1)
Mechanically ventilated patients	61/61 (100)
Study days	11.7 ± 0.8
ICU days	19.1 ± 1.6
Ventilator days	23.8 ± 2.3
Hospital days	31.7 ± 2.7
SOFA score	7.5 ± 0.6
APACHE II score	20.2 ± 0.9
Blood glucose level (mg/dL)	184.7 ± 8.6
ICU mortality rate	18/61 (29.5)
Admission diagnosis
Pneumonia	19/61 (31.1)
Sepsis	18/61 (29.5)
CHF	6/61 (9.8)
ARDS	6/61 (9.8)
Stroke	5/61 (8.2)
COPD or asthma	5/61 (8.2)
Myocardial infarction	1/61 (1.6)
Toxic overdose	1/61 (1.6)

ICU: Intensive care unit; SOFA: Sequential organ failure assessment; APACHE: Acute physiology and chronic health evaluation; CHF: Congestive heart failure; ARDS: Acute respiratory distress syndrome; COPD: Chronic obstructive pulmonary disease.

Table 2 Difference of GRV1 and PDay12 between survivors and non-survivors (mean ± SE)

	Non-survivors (n = 18)	Survivors (n = 43)
GRV1 (mL)	74.4 ± 31.0	38.0 ± 6.9
PDay12	-1.1 ± 0.6	0.3 ± 0.1

GRV1: Gastric residual volume on the first day; GRV2: Gastric residual volume on the second day. PDay12 = (GRV1 - GRV2)/GRV1.